Zytiga gets Canadian green light for prostate cancer
This article was originally published in Scrip
Executive Summary
Janssen ( Johnson & Johnson) has received Canadian regulatory approval for its once-daily oral product, Zytiga (abiraterone acetate), to be used with prednisone to treat men with metastatic castrate-resistant prostate cancer who have previously been treated with docetaxel.